Community compliance with carcinoembryonic antigen: Follow-up of patients with colorectal cancer

Clinical Colorectal Cancer

Volumn 7, Issue 2, 2008, Pages 118-125

  Spratlin, Jennifer L ^a,b   Hui, David ^a   Hanson, John ^b   Butts, Charles ^a,b   Au, Heather Jane ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

Author keywords

Clinical practice guidelines; Consultation; Family physicians; Radiation therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; COMMUNITY CARE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POPULATION RECOVERY; PRACTICE GUIDELINE; PROTEIN BLOOD LEVEL; TUMOR RECURRENCE;

EID: 42049108376     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2008.n.016     Document Type: Article

References (36)

1. American Cancer Society [Web site]. Cancer Facts and Figures, 2007. Available at: www.cancer.org. Accessed: September 10, 2007.
2. AJCC Cancer Staging Manual. 6th ed. New York, New York: Springer; 2002.
3. Ohlsson B, Breland U, Ekberg H, et al. Follow-up after curative surgery for colorectal carcinoma. Randomized comparison with no follow-up. Dis Colon Rectum 1995; 38:619-26.
4. Schoemaker D, Black R, Giles L, et al. Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients. Gastroenterology 1998; 114:7-14.
5. Pietra N, Sarli L, Costi R, et al. Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. Dis Colon Rectum 1998; 41:1127-33.
6. Makela JT, Laitinen SO, Kairaluoma MI. Five-year follow-up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Arch Surg 1995; 130:1062-7.
7. Secco GB, Fardelli R, Gianquinto D, et al. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. Eur J Surg Oncol 2002; 28:418-23.
8. McCall JL, Black RB, Rich CA, et al. The value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancer. Dis Colon Rectum 1994; 37:875-81.
9. Bakalakos EA, Burak WE, Jr, Young DC, et al. Is carcino-embryonic antigen useful in the follow-up management of patients with colorectal liver metastases? Am J Surg 1999; 177:2-6.
10. Kjeldsen BJ, Kronborg O, Fenger C, et al. A prospective randomized study of follow-up after radical surgery for colorectal cancer. Br J Surg 1997; 84:666-9.
11. Desch CE, Benson AB 3rd, Somerfield MR, et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2005; 23:8512-9.
12. Benson AB 3rd, Desch CE, Flynn PJ, et al. 2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines. J Clin Oncol 2000; 18:3586-8.
13. Desch CE, Benson AB 3rd, Smith TJ, et al. Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology. J Clin Oncol 1999; 17:1312.
14. Chau I, Allen MJ, Cunningham D, et al. The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. J Clin Oncol 2004; 22:1420-9.
15. Renehan AG, Egger M, Saunders MP, et al. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ 2002; 324:813.
16. Grunfeld E, Levine MN, Julian JA, et al. Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. J Clin Oncol 2006; 24:848-55.
17. Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005; 23:8664-70.
18. Worrall G, Chaulk P, Freake D. The effects of clinical practice guidelines on patient outcomes in primary care: a systematic review. CMAJ 1997; 156:1705-12.
19. Bennett CL, Somerfield MR, Pfister DG, et al. Perspectives on the value of American Society of Clinical Oncology clinical guidelines as reported by oncologists and health maintenance organizations. J Clin Oncol 2003; 21:937-41.
20. Ray-Coquard I, Philip T, de Laroche G, et al. Persistence of medical change at implementation of clinical guidelines on medical practice: a controlled study in a cancer network. J Clin Oncol 2005; 23:4414-23.
21. Rosser WW, Davis D, Gilbart E. Promoting effective guideline use in Ontario. CMAJ 2001; 165:181-2.
22. Eddy DM. Clinical decision making: from theory to practice. Practice policies-guidelines for methods. JAMA 1990; 263:1839-41.
23. Browman GP, Makarski J, Robinson P, et al. Practitioners as experts: the influence of practicing oncologists "in-the-field" on evidence-based guideline development. J Clin Oncol 2005; 23:113-9.
24. Davis DA, Taylor-Vaisey A. Translating guidelines into practice. A systematic review of theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines. CMAJ 1997; 157:408-16.
25. Gold JM, Banjo C, Freedman SO, et al. Immunochemical studies of the intramolecular heterogeneity of the carcinoembryonic antigen (CEA) of the human digestive system. J Immunol 1973; 111:1872-9.
26. Gold P, Freedman SO. Tests for carcinoembryonic antigen. Role in diagnosis and management of cancer. JAMA 1975; 234:190-2.
27. Gold P, Wilson T, Romero R, et al. Immunology and colonic cancer: further evaluation of the radioimmunoassay for carcinoembryonic antigen of the human digestive system as an adjunct in cancer diagnosis. Dis Colon Rectum 1973; 16:358-65.
28. Benchimol S, Fuks A, Jothy S, et al. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 1989; 57:327-34.
29. Fletcher RH. Carcinoembryonic antigen. Ann Intern Med 1986; 104:66-73.
30. Li Destri G, Rinzivillo C, Craxi G, et al. Colorectal follow-up planning modified on the basis of our personal experience. Dig Surg 1998; 15:64-8.
31. Tartter PI, Slater G, Gelernt I, et al. Screening for liver metastases from colorectal cancer with carcinoembryonic antigen and alkaline phosphatase. Ann Surg 1981; 193:357-60.
32. Bruinvels DJ, Stiggelbout AM, Kievit J, et al. Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg 1994; 219:174-82.
33. Arnaud JP, Bergamaschi R, Casa C, et al. The rational for CEA dosage in the follow-up of patients operated for colorectal cancer. A prospective study on 800 cases. Spec Int Col Mtg Surg Oncol 1992; 25.
34. Grunfeld E, Mant D, Yudkin P, et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ 1996; 313:665-9.
35. Grunfeld E, Fitzpatrick R, Mant D, et al. Comparison of breast cancer patient satisfaction with follow-up in primary care versus specialist care: results from a randomized controlled trial. Br J Gen Pract 1999; 49:705-10.
36. Grunfeld E, Gray A, Mant D, et al. Follow-up of breast cancer in primary care vs specialist care: results of an economic evaluation. Br J Cancer 1999; 79:1227-33.